Jessy Shi

-Product development strategy: lead the PDP planning for novel anti-HER2 mab, Daratumuab biosimilar, Denosumab biosimilar, Pertuzumab biosmilar, supported in novel anti-EGFR clinical strategy planning, through desk research, internal consultation with medical experts, statisticians -Business intelligence: conducted global and Chinese business intelligence on PD-(L)1 competition landscape, including clinical development status, trial designs -Clinical strategy: catch up with the new literature and published data on PD-(L)1 development, and provide recommendation on HLX10 development strategy, including go/no-go decision, indication prioritization, study design, country selection, etc. -Regulation research: deep dive in NMPA and FDA regulatory requirement in accelerated approval, combination therapy development, to support the global strategy -Others: act as a mentor for new team member on-job training

Focus on biologics in oncology and anto-immune disease -Competition Landscape : update the competive intelligence countinously, including progress of innovative or biosimilar develoment, comptitor company profile and regulatory policy -Disease landscape: develop disease treatment flows, mainly in oncology and auto-immune disease -Feasibility analysis: evaluate feasibility of new drug develoment in aspect of market potential, competition, and NPV, to support R&D and BD project

- Joined as CRA trainee, and recieved 4-month systematic training on clinical trial operation - Completed 10 Site Selection Visits of 3 clinical trials, and 1 Site Initiation Visit - Participated in 1 self-inspection project